Effects of UK 69 578: a novel atriopeptidase inhibitor

Lancet. 1989 Sep 9;2(8663):591-3. doi: 10.1016/s0140-6736(89)90714-9.

Abstract

UK 69 578 is a competitive inhibitor of endopeptidase 24.11 (the enzyme that degrades atrial natriuretic factor) in vitro. In vivo, UK 69 578 has renal and cardiovascular effects similar to low-dose atrial natriuretic factor infusion, and may be a useful agent in hypertension and heart failure.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Animals
  • Atrial Natriuretic Factor / antagonists & inhibitors*
  • Atrial Natriuretic Factor / blood
  • Clinical Trials as Topic
  • Coronary Disease / blood
  • Coronary Disease / drug therapy
  • Cyclohexanecarboxylic Acids*
  • Dogs
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Evaluation
  • Drug Evaluation, Preclinical
  • Half-Life
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Natriuresis / drug effects
  • Nephrectomy
  • Neprilysin / antagonists & inhibitors*
  • Neprilysin / blood
  • Neprilysin / pharmacology
  • Rats
  • Rats, Inbred Strains
  • Time Factors

Substances

  • Cyclohexanecarboxylic Acids
  • candoxatrilat
  • Atrial Natriuretic Factor
  • Neprilysin